QT Imaging Holdings (QTI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Jul, 2026Executive summary
Annual Meeting scheduled for July 28, 2026, to be held virtually; record date is June 23, 2026.
2025 revenue reached $18.9 million, a 288% increase from 2024, with gross margin at 45%.
Net loss for 2025 was $21.1 million, compared to $9.0 million in 2024; net cash used in operations decreased to $9.0 million.
Financial position strengthened by $18.2 million private placement and $5.0 million additional financing; uplisted to Nasdaq in January 2026.
Entered exclusive distribution agreements in Saudi Arabia and UAE for core products.
Voting matters and shareholder proposals
Election of two Class II directors (Bryan Timm and Professor Zeev Weiner) to serve until 2029.
Ratification of BPM LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Approval of amendment to 2024 Equity Incentive Plan to increase shares reserved for issuance by 550,900 to 2,378,178.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of seven members, classified into three classes with staggered three-year terms.
Majority of directors are independent per Nasdaq standards; separation of Chairman and CEO roles.
Board committees: Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and responsibilities.
All directors attended at least 87.5% of meetings in 2025.
Corporate governance guidelines, code of ethics, and insider trading policy in place.
Latest events from QT Imaging Holdings
- All proposals, including director elections and equity plan amendment, passed by wide margins.QTI
AGM 202630 Jul 2026 - Q1 2026 revenue rose 133% to $6.5M, with narrowed losses and ongoing risks from customer and region.QTI
Q1 20268 Jul 2026 - Annual meeting to vote on directors, auditor, and equity plan amid strong growth and governance.QTI
Proxy filing22 Jun 2026 - Q3 2025 revenue rose 339% to $4.2M; 2026 revenue outlook raised to $39M.QTI
Q3 202515 May 2026 - FDA-cleared 3D breast imaging platform drives rapid growth with AI and global partnerships.QTI
Investor presentation13 May 2026 - $2.56M PIPE financing and $1.0M Q3 revenue support liquidity amid ongoing commercialization.QTI
Q3 202422 Apr 2026 - Q2 2024 revenue hit $1.7M with 51% margin; net loss widened to $6.4M amid higher costs.QTI
Q2 202422 Apr 2026 - Q1 2025 revenue doubled to $2.8M with 65% margin; net loss widened to $11.1M.QTI
Q1 202522 Apr 2026 - Q2 revenue doubled to $3.7M, net loss widened, liquidity boosted by new financings.QTI
Q2 202522 Apr 2026